Tofogliflozin ameliorates cardiotoxin induced skeletal muscle injury and fibrosis in obesity

Abstract Obesity impairs muscle function through effects on lipid metabolism, systemic inflammation, and insulin resistance, leading to muscle loss and reduced regeneration. Tofogliflozin (Tofo), a sodium-glucose cotransporter 2 inhibitor (SGLT2i), exclusively inhibits SGLT2 and is used to treat hyp...

Descripció completa

Dades bibliogràfiques

Autors principals:	Muhammad Bilal, Nguyen Quynh Phuong, Tomonobu Kado, Jianhui Liu, Le Duc Anh, Sana Khalid, Muhammad Rahil Aslam, Memoona, Ayumi Nishimura, Yoshiko Igarashi, Yoshiyuki Watanabe, Waseem Abbas, Maki Yokoyama, Yasuhiro Onogi, Kenichi Hirabayashi, Seiji Yamamoto, Kunimasa Yagi, Marsel Lino, Isao Usui, Masaru Kato, Shiho Fujisaka, Allah Nawaz, Kazuyuki Tobe
Format:	Artigo
Idioma:	Inglês
Publicat:	Nature Portfolio 2025-10-01
Col·lecció:	Scientific Reports
Matèries:	Skeletal muscle Cardiotoxin-induced injury Fibro-adipogenic progenitors (FAPs) Follistatin Exercise tolerance
Accés en línia:	https://doi.org/10.1038/s41598-025-12734-9
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!